[go: up one dir, main page]

WO2009030676A3 - Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age - Google Patents

Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age Download PDF

Info

Publication number
WO2009030676A3
WO2009030676A3 PCT/EP2008/061527 EP2008061527W WO2009030676A3 WO 2009030676 A3 WO2009030676 A3 WO 2009030676A3 EP 2008061527 W EP2008061527 W EP 2008061527W WO 2009030676 A3 WO2009030676 A3 WO 2009030676A3
Authority
WO
WIPO (PCT)
Prior art keywords
age
years
pharmaceutical composition
vaccination
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/061527
Other languages
French (fr)
Other versions
WO2009030676A2 (en
Inventor
Erich Tauber
Shailesh Dewasthaly
Christoph Klade
Astrid Kaltenboeck
Elisabeth Schuller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of WO2009030676A2 publication Critical patent/WO2009030676A2/en
Publication of WO2009030676A3 publication Critical patent/WO2009030676A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising a cell culture derived, inactivated JEV for use in the treatment or prevention of an infection with JEV in a human subject with at least 40 years of age.
PCT/EP2008/061527 2007-09-03 2008-09-02 Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age Ceased WO2009030676A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115557 2007-09-03
EP07115557.6 2007-09-03

Publications (2)

Publication Number Publication Date
WO2009030676A2 WO2009030676A2 (en) 2009-03-12
WO2009030676A3 true WO2009030676A3 (en) 2009-07-02

Family

ID=40404491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/061527 Ceased WO2009030676A2 (en) 2007-09-03 2008-09-02 Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age

Country Status (1)

Country Link
WO (1) WO2009030676A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
CA2763794C (en) 2009-06-04 2017-01-17 Rotation Medical, Inc. Apparatus having bowstring-like staple delivery to a target tissue

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LYONS ET AL: "A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 25, no. 17, 5 April 2007 (2007-04-05), pages 3445 - 3453, XP022022123, ISSN: 0264-410X *
SCHIOLER K.L., SAMUEL M & WAI K.L.: "Vaccines for preventing Japanese encephalitis (review)", COCHRANE DATABASE SYST REV, vol. 3, no. CD004263, 18 July 2007 (2007-07-18), XP002518555, Retrieved from the Internet <URL:http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004263/pdf_fs.html> [retrieved on 20090310] *
SCHULLER E ET AL: "Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 26, no. 34, 12 August 2008 (2008-08-12), pages 4382 - 4386, XP023179650, ISSN: 0264-410X, [retrieved on 20080617] *
TAUBER ET AL: "Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 370, no. 9602, 29 November 2007 (2007-11-29), pages 1847 - 1853, XP022369933, ISSN: 0140-6736 *

Also Published As

Publication number Publication date
WO2009030676A2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2010085100A2 (en) Novel cellular transmembrane domain and intracellular transduction system containing the same
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
NZ607477A (en) Non-natural amino acid replication-dependent microorganisms and vaccines
MX2013003634A (en) Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases.
WO2009129470A3 (en) Methods for treating herpes virus infections
WO2011106376A3 (en) Use of microvesicles in the treatment of medical conditions
MX2012001882A (en) ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCTIAL VIRUS (RSV) AND METHODS OF USE.
WO2013014643A3 (en) Device, system and method for prosthodontic restoration
PH12014501620A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
WO2009024677A3 (en) Use of hyaluronic acid for preparing compositions for improving the function of skin, eye and mucous membrane protection
EP2471926A3 (en) Immunostimulatory oligodeoxynucleotides
WO2013048153A3 (en) Binding molecule having influenza a virus-neutralizing activity produced from human b cell
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
MX2009012922A (en) Intradermal hpv peptide vaccination.
EP4464375A3 (en) Methods of treatment using single doses of oritavancin
WO2011076367A3 (en) Synergistic antiviral composition and use thereof
WO2007101949A3 (en) Human interferon-gamma (infgamma) variants
WO2007006712A3 (en) Mycoplasma subunit vaccine
WO2009005040A1 (en) Pseudomonas aeruginosa outer membrane protein pa4710
WO2010041241A3 (en) Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
MX347911B (en) Bvdv vaccine.
WO2009030676A3 (en) Pharmaceutical composition comprising a japanese encephalitis virus for vaccination of patients of at least 40 years of age
WO2007147623A3 (en) A novel target in the treatment of cytokine release syndrome
EP2495252A3 (en) Soluble forms of hendra and nipah virus G glycoprotein
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08803502

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08803502

Country of ref document: EP

Kind code of ref document: A2